Non-Clinical Toxicity Services
Assess local toxicity upon injection in ex vivo live human skin
Non-Clinical Toxicity Services
Assess local toxicity upon injection in ex vivo live human skin
Predicting unwanted inflammatory responses with advanced ex vivo services
Unanticipated local reactions can frequently emerge during clinical trials, leading to discomfort for patients and decreased adherence to treatment. At Genoskin, we have developed specialized ex vivo platforms tailored for non-clinical toxicity services. These platforms are ideal for evaluating potential inflammatory reactions to injections before therapeutics reach clinical trial stages or the market. You can assess inflammatory responses to subcutaneous, transdermal, and intradermal vaccines, therapeutics, and medical devices. Dive into the key features and advantages of this unique platform.
Innovative
Pioneering the future of non-clinical drug safety with cutting-edge platforms.
Human
Leveraging animal-free technology for unparalleled accuracy ahead of clinical trials.
Toxicity
Diving deep into unwanted reactions, ensuring every therapeutic is safe.
Characterization
Comprehensive insights into drug-induced immune reactions for enhanced prediction.
Obtain immune data from a unique injectable platform
Genoskin’s non-clinical toxicity services offer an innovative first-in-human approach to help you detect and understand potential injection site reactions. This ensures you select the best drug candidate and secure the continuity of your development process. We inject your drug or vaccine into a healthy, biostabilized, and immunocompetent human HypoSkin® model to characterize potential ISRs.
The HypoSkin® platform contains real human epidermis, dermis, adipose tissue and all native human skin appendages and immune cells. These models are particularly suited to test injection site reactions ex vivo. Moreover, it allows the observation of the response from live human skin to your vaccine or therapeutic candidate in live human skin for an entire week.
Cellular toxicity studies on human primary mast cells
Genoskin’s research emphasizes the importance of human primary mast cells in drug toxicity assessment. Traditional research tools often fall short, especially when studying mast cells, as human primary mast cells are challenging to obtain. Genoskin offers a unique solution, providing access to connective-tissue type human primary mast cells to understand the underlying mechanisms of action with certain injection site reactions. These mast cells play a crucial role in the immune system’s response to various stimuli. With Genoskin’s platforms, researchers can obtain reliable human data prior to entering clinical trials, ensuring a comprehensive understanding of potential toxicity reactions and enhancing the safety of drug development.
The human primary cells developed by Genoskin are fully differentiated and express the MRGPRX2, FcεR1ɑ and KIT receptors.
